Medtronic reported its Q2 fiscal year 2026 results (ended in October):
Revenue: +6.6% YoY — exceeding market expectations.
EPS: +7.9% YoY — also beating forecasts.
Cardiovascular segment: Grew by 10.8%.
Growth Drivers:
Technological Breakthroughs:
Affera & Sphere-9: The cardiac mapping system’s install base doubled during the quarter.
Symplicity Spyral: This hypertension treatment device has received approval from major US insurers (covering 30 million lives). The potential market is estimated at 18 million patients in the US alone.
Strategic Moves:
Within this calendar year, Medtronic is spinning off its diabetes division into a separate company, MiniMed. This is expected to unlock hidden value for shareholders and allow the core business to focus on higher-margin products.
On February 3, 2026, Medtronic announced its intention to acquire CathWorks for $585 million. The deal provides access to the FFRangio system, a non-invasive technology for diagnosing coronary artery disease, further strengthening a cardiology portfolio that accounts for nearly 40% of total revenue.
Dividends:
The company has raised its dividend for 47 consecutive years. The 48th increase is expected in just a few months.
Dividend yield: ~2.8%
Technical Analysis:
The stock is currently trading within an ascending channel.
The price has broken through a local resistance level and successfully completed a retest.
Revenue: +6.6% YoY — exceeding market expectations.
EPS: +7.9% YoY — also beating forecasts.
Cardiovascular segment: Grew by 10.8%.
Growth Drivers:
Technological Breakthroughs:
Affera & Sphere-9: The cardiac mapping system’s install base doubled during the quarter.
Symplicity Spyral: This hypertension treatment device has received approval from major US insurers (covering 30 million lives). The potential market is estimated at 18 million patients in the US alone.
Strategic Moves:
Within this calendar year, Medtronic is spinning off its diabetes division into a separate company, MiniMed. This is expected to unlock hidden value for shareholders and allow the core business to focus on higher-margin products.
On February 3, 2026, Medtronic announced its intention to acquire CathWorks for $585 million. The deal provides access to the FFRangio system, a non-invasive technology for diagnosing coronary artery disease, further strengthening a cardiology portfolio that accounts for nearly 40% of total revenue.
Dividends:
The company has raised its dividend for 47 consecutive years. The 48th increase is expected in just a few months.
Dividend yield: ~2.8%
Technical Analysis:
The stock is currently trading within an ascending channel.
The price has broken through a local resistance level and successfully completed a retest.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.